B-MS and Medarex initiate collaboration

Published: 1-Feb-2005


Bristol-Myers Squibb and Medarex have started their global development and commercialisation collaboration to jointly develop MDX-010, a fully human antibody investigational product targeting the CTLA-4 receptor that is currently in Phase III clinical trials for the treatment of metastatic melanoma.

Medarex will receive an initial cash payment of $50m, of which $25m will be for a purchase of Medarex's common stock by B-MS. In addition, the company could receive up to $205m if all regulatory milestones are met, and up to $275m in sales-related milestones. Medarex has an option to co-promote and share profits with B-MS in the US. Bristol-Myers Squibb will receive an exclusive licence outside the US and will pay royalties.

You may also like